Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2019

01-04-2019 | Epidemiology

Yield of surveillance magnetic resonance imaging after bilateral mastectomy and reconstruction: a retrospective cohort study

Authors: Orit Golan, Yoav Amitai, Yoav Barnea, Tehillah S. Menes

Published in: Breast Cancer Research and Treatment | Issue 2/2019

Login to get access

Abstract

Purpose

There are no evidence-based guidelines for surveillance of women after bilateral mastectomy and reconstruction. Several societies recommend against routine breast imaging in this setting. Despite these recommendations, magnetic resonance imaging (MRI) is frequently used to follow these women. We sought to examine the findings on MRI studies done in this setting.

Methods

This is a retrospective cohort study including all consecutive MRI exams done after bilateral mastectomy and reconstruction between January 2010 and April 2018. Data collected included demographic information, family history, BRCA status, indication for bilateral mastectomy, type of reconstruction, findings on MRI, and work-up of MRI findings. Cancer detection rate and interval cancer rates were calculated.

Results

One hundred fifty-nine women had 415 surveillance MRI exams. Most (372, 90%) studies were done in women with implant-based reconstruction. Four hundred and five (98%; 95% confidence interval (CI) 96–99%) of the studies were negative. One breast recurrence was found on MRI (cancer detection rate 2.4 per 1000 MRI exams, 95% CI 0.4–13); however, this woman was simultaneously diagnosed with metastatic disease. The false-positive rate was 90% (95% CI 54–99%). During follow-up three women were diagnosed with local recurrence (interval cancer rate 5 per 1000, 95% CI 1.3–17) and 4 women were diagnosed with metastatic disease.

Conclusion

The yield of surveillance MRI in women with bilateral mastectomy and reconstruction is very low. As most of the cohort had retro-pectoral implant-based reconstruction, it appears safe to recommend against surveillance MRI in this setting regardless of the indication for mastectomy.
Literature
3.
go back to reference Allain DC, Sweet K, Agnese DM (2007) Management options after prophylactic surgeries in women with BRCA mutations: a review. Cancer control 14:330–337CrossRefPubMed Allain DC, Sweet K, Agnese DM (2007) Management options after prophylactic surgeries in women with BRCA mutations: a review. Cancer control 14:330–337CrossRefPubMed
4.
go back to reference Horsman D, Wilson BJ, Avard D et al on behalf of the National Hereditary Cancer Task Force (2007) Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. Obstet Gynaecol Can 29:45–60CrossRef Horsman D, Wilson BJ, Avard D et al on behalf of the National Hereditary Cancer Task Force (2007) Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. Obstet Gynaecol Can 29:45–60CrossRef
5.
go back to reference Destounis S, Morgan R, Arieno A, Seifert P, Somerville P, Murphy P (2011) A review of breast imaging following mastectomy with or without reconstruction in an outpatient community center. Breast Cancer 18:259–267CrossRefPubMed Destounis S, Morgan R, Arieno A, Seifert P, Somerville P, Murphy P (2011) A review of breast imaging following mastectomy with or without reconstruction in an outpatient community center. Breast Cancer 18:259–267CrossRefPubMed
6.
go back to reference Madorsky-Feldman D, Sklair-Levy M, Perri T et al (2016) An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 157:319–327CrossRefPubMedPubMedCentral Madorsky-Feldman D, Sklair-Levy M, Perri T et al (2016) An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 157:319–327CrossRefPubMedPubMedCentral
7.
go back to reference Zakhireh J, Fowble B, Esserman LJ (2010) Application of screening principles to the reconstructed breast. J Clin Oncol 28:173–180CrossRefPubMed Zakhireh J, Fowble B, Esserman LJ (2010) Application of screening principles to the reconstructed breast. J Clin Oncol 28:173–180CrossRefPubMed
8.
go back to reference Barnsley GP, Grunfeld E, Coyle D, Paszat L (2007) Surveillance mammography following the treatment of primary breast cancer with breast reconstruction: a systematic review. Plast Reconstr Surg 120:1125–1132CrossRefPubMed Barnsley GP, Grunfeld E, Coyle D, Paszat L (2007) Surveillance mammography following the treatment of primary breast cancer with breast reconstruction: a systematic review. Plast Reconstr Surg 120:1125–1132CrossRefPubMed
10.
go back to reference Torresan RZ, dos Santos CC, Okamura H, Alvarenga M (2005) Evaluation of residual glandular tissue after skin sparing mastectomies. Ann Surg Oncol 12:1037–1044CrossRefPubMed Torresan RZ, dos Santos CC, Okamura H, Alvarenga M (2005) Evaluation of residual glandular tissue after skin sparing mastectomies. Ann Surg Oncol 12:1037–1044CrossRefPubMed
11.
go back to reference Lee JM, Georgian-Smith D, Gazelle GS et al (2008) Detecting nonpalpable recurrent breast cancer: the role of routine mammographic screening of transverse rectus abdominis myocutaneous flap reconstructions. Radiology 248:398–405CrossRefPubMed Lee JM, Georgian-Smith D, Gazelle GS et al (2008) Detecting nonpalpable recurrent breast cancer: the role of routine mammographic screening of transverse rectus abdominis myocutaneous flap reconstructions. Radiology 248:398–405CrossRefPubMed
12.
go back to reference Helvie MA, Bailey JE, Roubidoux MA et al (2002) Mammographic screening of TRAM flap breast reconstructions for detection of nonpalpable recurrent cancer. Radiology 224:211–216CrossRefPubMed Helvie MA, Bailey JE, Roubidoux MA et al (2002) Mammographic screening of TRAM flap breast reconstructions for detection of nonpalpable recurrent cancer. Radiology 224:211–216CrossRefPubMed
13.
go back to reference Noroozian M, Carlson LW, Savage JL et al (2018) Use of screening mammography to detect occult malignancy in autologous breast reconstructions: a 15-year experience. Radiology 289:39–48CrossRefPubMed Noroozian M, Carlson LW, Savage JL et al (2018) Use of screening mammography to detect occult malignancy in autologous breast reconstructions: a 15-year experience. Radiology 289:39–48CrossRefPubMed
14.
go back to reference Clark L, Ritter E, Glazebrook K, Tyler D (1999) Recurrent ductal carcinoma in situ after total mastectomy. J Surg Oncol 71:182–185CrossRefPubMed Clark L, Ritter E, Glazebrook K, Tyler D (1999) Recurrent ductal carcinoma in situ after total mastectomy. J Surg Oncol 71:182–185CrossRefPubMed
15.
go back to reference Vanderwalde LH, Dang CM, Tabrizi R, Saouaf R, Phillips EH (2011) Breast MRI after bilateral mastectomy: is it indicated? Am Surg 77:180–184PubMed Vanderwalde LH, Dang CM, Tabrizi R, Saouaf R, Phillips EH (2011) Breast MRI after bilateral mastectomy: is it indicated? Am Surg 77:180–184PubMed
16.
go back to reference Pinel-Giroux FM, El Khoury MM, Trop I, Bernier C, David J, Lalonde L (2013) Breast reconstruction: review of surgical methods and spectrum of imaging findings. Radiographics 33:435–453CrossRefPubMed Pinel-Giroux FM, El Khoury MM, Trop I, Bernier C, David J, Lalonde L (2013) Breast reconstruction: review of surgical methods and spectrum of imaging findings. Radiographics 33:435–453CrossRefPubMed
17.
go back to reference Buchanan CL, Dorn PL, Fey J et al (2006) Locoregional recurrence after mastectomy: incidence and outcomes. J Am Coll Surg 203:469–474CrossRefPubMed Buchanan CL, Dorn PL, Fey J et al (2006) Locoregional recurrence after mastectomy: incidence and outcomes. J Am Coll Surg 203:469–474CrossRefPubMed
Metadata
Title
Yield of surveillance magnetic resonance imaging after bilateral mastectomy and reconstruction: a retrospective cohort study
Authors
Orit Golan
Yoav Amitai
Yoav Barnea
Tehillah S. Menes
Publication date
01-04-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-05077-9

Other articles of this Issue 2/2019

Breast Cancer Research and Treatment 2/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine